
RealRate

PHARMACEUTICAL 2022

MADRIGAL PHARMACEUTICALS INC.



Rank 455 of 475



RealRate

PHARMACEUTICAL 2022

MADRIGAL PHARMACEUTICALS INC.



Rank 455 of 475

The relative strengths and weaknesses of MADRIGAL PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MADRIGAL PHARMACEUTICALS INC. compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 132% points. The greatest weakness of MADRIGAL PHARMACEUTICALS INC. is the variable Net Income, reducing the Economic Capital Ratio by 547% points.

The company's Economic Capital Ratio, given in the ranking table, is -912%, being 636% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	271,684
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	76,838
Liabilities, Non-Current	387
Other Assets	797
Other Compr. Net Income	-127
Other Expenses	205,164
Other Liabilities	0
Other Net Income	363
Property and Equipment	851
Research and Development	205,164
Revenues	273
Selling, General and Administrative Expense	37,318

Output Variable	Value in 1000 USD
Assets	273,332
Liabilities	77,225
Expenses	447,646
Stockholders Equity	196,107
Net Income	-447,010
Comprehensive Net Income	-447,074
Economic Capital Ratio	-912%